Citations

Clear

3138 citation(s) found for "Smith, AM".

Primary Vitreoretinal Lymphoma: A Report from an International Primary Central Nervous System Lymphoma Collaborative Group Symposium
Chan, Chi-Chao, Rubenstein, James L. , Coupland, Sarah E. , Davis, Janet L. , Johnston, Patrick B. , Cassoux, Nathalie , Touitou, Valérie , Smith, Justine R. , Batchelor, Tracy T. , Pulido, José S. , Harbour, J. William , Smith, Justine

Mayo Clinic

The Oncologist | November 1, 2011 | Volume: 16 | Issue: 11 | Pages: 1589-1599

10.1634/theoncologist.2011-0210 | PMID 22045784 Get It

Abstract Primary vitreoretinal lymphoma (PVRL), also known as primary intraocular lymphoma, is a rare malignancy typically classified as a diffuse large B-cell lymphoma and most frequently develops in elderly populations. PVRL commonly masquerades as posterior uveitis and has a unique tropism for the retina and central nervous system (CNS). Over 15% of primary CNS lymphoma patients develop intraocular lymphoma, usually occurring in the retina and/or vitreous. Conversely, 65%–90% of PVRL patients develop CNS lymphoma. Consequently, PVRL is often fatal because of ultimate CNS association. Current PVRL animal models are limited and require further development. Typical clinical findings include vitreous cellular infiltration (lymphoma and inflammatory cells) and subretinal tumor infiltration as determined using dilated fundoscopy, fluorescent angiography, and optical coherent tomography. Currently, PVRL is most often diagnosed using both histology to identify lymphoma cells in the vitreous or retina and immunohistochemistry to indicate monoclonality. Additional adjuncts in diagnosing PVRL exist, including elevation of interleukin-10 levels in ocular fluids and detection of IgH or T-cell receptor gene rearrangements in malignant cells. The optimal therapy for PVRL is not defined and requires the combined effort of oncologists and ophthalmologists. PVRL is sensitive to radiation therapy and exhibits high responsiveness to intravitreal methotrexate or rituximab. Although systemic chemotherapy alone can result in high response rates in patients with PVRL, there is a high relapse rate. Because of the disease rarity, international, multicenter, collaborative efforts are required to better understand the biology and pathogenesis of PVRL as well as to define both diagnostic markers and optimal therapies.
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
Karp, Judith E. , Vener, Tatiana, Raponi, Mitch , Ritchie, Ellen K. , Gore, Steven D. , Morris, Lawrence E. , Feldman, Eric J. , Greer, Jacqueline M., Malek, Sami N. , Ironside, Valerie, Galkin, Steven, McDevitt, Michael A. , Roboz, G., Gocke, Christopher D. , Derecho, Carlo, Palma, John F. , Wright, John J., Garret-Mayer, Elizabeth, Smith, Benjamin D. , Carraway, Hetty E. , Levis, Mark J. , Roboz, Gail J. , Wang, Yixin , Kaufmann, Scott H. , Wright, John J.

Mayo Clinic

Blood | October 15, 2011 | Volume: 119 | Issue: 1 | Pages: 55-63

10.1182/blood-2011-08-370825 | PMID 22001391 Get It

Abstract Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25% complete remission (CR). We selected 2 comparable dose levels for a randomized phase 2 trial in 84 adults (age range, 70-90 years; median, 76 years) who were not candidates for conventional chemotherapy. Arm A (T 600 mg twice a day × 14 days, E 100 mg days 1-3 and 8-10) and arm B (T 400 mg twice a day × 14 days, E 200 mg days 1-3 and 8-10) yielded similar CR, but arm B had greater toxicity. Total CR was 25%, day 30 death rate 7%. A 2-gene signature of high RASGRP1 and low aprataxin (APTX) expression previously predicted for T response. Assays using blasts from a subset of 40 patients treated with T plus E on this study showed that AMLs with a RASGRP1/APTX ratio of more than 5.2 had a 78% CR rate and negative predictive value 87%. This ratio did not correlate with outcome in 41 patients treated with conventional chemotherapies. The next T-based clinical trials will test the ability of the 2-gene signature to enrich for T responders prospectively. This study is registered at www.clinicaltrials.gov as #NCT00602771.
Clinical and radiological features of respiratory syncytial virus in solid organ transplant recipients: a single‐center experience
Ariza‐Heredia, Ella , Fishman, Joel E. , Smith, Laura, Abbo, Lilian, Cleary, Timothy J. , Razonable, Raymund R.

Mayo Clinic

Transplant Infectious Disease | October 7, 2011 | Volume: 14 | Issue: 1 | Pages: 64-71

10.1111/j.1399-3062.2011.00673.x | PMID 22093238 Get It

Abstract:BackgroundRespiratory syncytial virus (RSV) infections range from upper respiratory illness to severe lower respiratory disease. There is no universally accepted treatment for RSV in solid organ transplant (SOT) recipients.MethodsRetrospective review of adult SOT patients with RSV infections, between January 2007 and December 2009, in a single transplant center was performed.ResultsDuring the 3‐year period, a total of 24 adults developed RSV infection, including 12 (50%) SOT recipients (5 kidneys, 4 livers, and 3 lungs). Most cases were seen in 2009 during the influenza H1N1 pandemic, likely as a result of increased testing. In 83% of the cases, the diagnosis was based on RSV antigen detection, which was also used to follow subsequent shedding (mean duration: 20.6 days). Most of the cases presented with lower respiratory disease and required hospitalization. All the patients were on at least two classes of immunosuppressive drugs. We observed a lower lymphocyte count in patients with lower respiratory tract infection. Computed tomography was superior to chest x‐ray in demonstrating pulmonary disease, with the most common findings being pulmonary nodules and ground‐glass opacities. Novel radiographic findings were small cavities and pleural effusions. No co‐infections were documented, and no mortality could be attributed to RSV. Inhaled or oral ribavirin was administered in 67% of the cases, with variations in the treatment regimens.ConclusionSOT recipients accounted for half of all adult cases of RSV at our institution. Type and length of treatment varied widely, and we cannot conclude that outcomes differed between treatments with oral or inhaled ribavirin. Current therapeutic management of RSV in SOT is empiric, and can be rather expensive and difficult, without clear evidence of effectiveness.
Posterior Reversible Encephalopathy Syndrome as a Cause of Postoperative Blindness
Barbara, David W. , Onigkeit, James A., Smith, Benjamin , Hemmings, Hugh C.

Mayo Clinic

Anesthesiology | October 4, 2011 | Volume: 116 | Issue: 2 | Pages: 472-472

10.1097/aln.0b013e3182315ed0 | PMID 21881490 Get It

Gemcitabine Plus nab -Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Hoff, Daniel D. Von , Ramanathan, Ramesh K., Laheru, Daniel A. , Smith, Lon, Wood, Tina E., Korn, Ronald L. , Desai, Neil, Trieu, Vuong , Iglesias, J. L. Mesías, Zhang, Hui , Soon‐Shiong, Patrick , Shi, Tao , Rajeshkumar, N.V., Maitra, Anirban , Hidalgo, Manuel , Borad, Mitesh J.

Mayo Clinic

Journal of Clinical Oncology | October 4, 2011 | Volume: 29 | Issue: 34 | Pages: 4548-4554

10.1200/jco.2011.36.5742 | PMID 21969517 Get It

Purpose The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and to provide efficacy and safety data. Additional objectives were to evaluate positron emission tomography (PET) scan response, secreted protein acidic and rich in cysteine (SPARC), and CA19-9 levels in relation to efficacy. Subsequent preclinical studies investigated the changes involving the pancreatic stroma and drug uptake. Patients and Methods Patients with previously untreated advanced pancreatic cancer were treated with 100, 125, or 150 mg/m 2 nab-paclitaxel followed by gemcitabine 1,000 mg/m 2 on days 1, 8, and 15 every 28 days. In the preclinical study, mice were implanted with human pancreatic cancers and treated with study agents. Results A total of 20, 44, and three patients received nab-paclitaxel at 100, 125, and 150 mg/m 2 , respectively. The MTD was 1,000 mg/m 2 of gemcitabine plus 125 mg/m 2 of nab-paclitaxel once a week for 3 weeks, every 28 days. Dose-limiting toxicities were sepsis and neutropenia. At the MTD, the response rate was 48%, with 12.2 median months of overall survival (OS) and 48% 1-year survival. Improved OS was observed in patients who had a complete metabolic response on [ 18 F]fluorodeoxyglucose PET. Decreases in CA19-9 levels were correlated with increased response rate, progression-free survival, and OS. SPARC in the stroma, but not in the tumor, was correlated with improved survival. In mice with human pancreatic cancer xenografts, nab-paclitaxel alone and in combination with gemcitabine depleted the desmoplastic stroma. The intratumoral concentration of gemcitabine was increased by 2.8-fold in mice receiving nab-paclitaxel plus gemcitabine versus those receiving gemcitabine alone. Conclusion The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse effects with substantial antitumor activity, warranting phase III evaluation.
Differential effects of eNOS uncoupling on conduit and small arteries in GTP-cyclohydrolase I-deficient hph-1 mice
Katušić, Zvonimir S. , d’Uscio, Livius V. , Smith, Leslie

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | October 1, 2011 | Volume: 301 | Issue: 6 | Pages: H2227-H2234

10.1152/ajpheart.00588.2011 | PMID 21963838 Get It

In the present study, we used the hph-1 mouse, which displays GTP-cyclohydrolase I (GTPCH I) deficiency, to test the hypothesis that loss of tetrahydrobiopterin (BH4) in conduit and small arteries activates compensatory mechanisms designed to protect vascular wall from oxidative stress induced by uncoupling of endothelial nitric oxide synthase (eNOS). Both GTPCH I activity and BH4levels were reduced in the aortas and small mesenteric arteries of hph-1 mice. However, the BH4-to-7,8-dihydrobiopterin ratio was significantly reduced only in hph-1 aortas. Furthermore, superoxide anion and 3-nitrotyrosine production were significantly enhanced in aortas but not in small mesenteric arteries of hph-1 mice. In contrast to the aorta, protein expression of copper- and zinc-containing superoxide dismutase (CuZnSOD) was significantly increased in small mesenteric arteries of hph-1 mice. Protein expression of catalase was increased in both aortas and small mesenteric arteries of hph-1 mice. Further analysis of endothelial nitric oxide synthase (eNOS)/cyclic guanosine monophosphate (cGMP) signaling demonstrated that protein expression of phosphorylated Ser1177-eNOS as well as basal cGMP levels and hydrogen peroxide was increased in hph-1 aortas. Increased production of hydrogen peroxide in hph-1 mice aortas appears to be the most likely mechanism responsible for phosphorylation of eNOS and elevation of cGMP. In contrast, upregulation of CuZnSOD and catalase in resistance arteries is sufficient to protect vascular tissue from increased production of reactive oxygen species generated by uncoupling of eNOS. The results of our study suggest that anatomical origin determines the ability of vessel wall to cope with oxidative stress induced by uncoupling of eNOS.
Primary headache syndromes in systemic mastocytosis
Butterfield, Joseph H. , Cutrer, F. Michael , Smith, Jonathan H.

Mayo Clinic

Cephalalgia | September 30, 2011 | Volume: 31 | Issue: 15 | Pages: 1522-1531

10.1177/0333102411421683 | PMID 21960649 Get It

Aim: To investigate the relationship between clinical mast cell activity and primary headache syndromes. Methods: We surveyed individuals with systemic mastocytosis, an uncommon disorder associated with increased mast cell activity. Diagnoses of primary headache syndromes in addition to the relationship of headache and symptoms of mastocytosis were ascertained. Results: A response rate of 64/148 (43.2%) was achieved. Headache diagnoses in our respondents (n = 64) were largely migraine (37.5%) and tension-type headaches (17.2%). Typical aura with and without migraine headache was highly represented in our patient population (n = 25, 39%). Three individuals met criteria for primary cough headache (4.7%). Symptoms reflective of mast cell activity were significantly greater in individuals reporting headaches. Patients experiencing headache concurrently with mastocytosis flairs were more likely to be male (p = 0.002), have histaminergic symptoms, such as itching (p = 0.02) and runny nose (p = 0.03), and have unilateral cranial autonomic features (p = 0.04). However, using standardized International Headache Society criteria, we did not identify individuals with cluster headache or other trigeminal autonomic cephalalgias in this population. Conclusions: Our observational survey-based data supports a clinical relationship between mast cell activity and primary headache syndromes. Generalizability of our results is limited by the low response rate and possible tertiary referral bias.
The Retained Surgical Specimen, an Unappreciated Retained Foreign Object
Smith, C. Daniel

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | September 28, 2011 | Volume: 21 | Issue: 8 | Pages: 737-739

10.1089/lap.2011.0368 | PMID 21954842 Get It

Rapid Detection of Coronary Artery Stenoses With Real-Time Perfusion Echocardiography During Regadenoson Stress
Porter, Thomas R. , Adolphson, Mary, High, Robin , Olson, Joan, Erdkamp, Michelle, Xie, Feng , O’Leary, Edward , Wong, Benjamin F., Eifert-Rain, Susan, Hagen, Mary E., Abdelmoneim, Sahar S. , Smith, Lynette M. , Mulvagh, Sharon L.

Mayo Clinic

Circulation: Cardiovascular Imaging | September 24, 2011 | Volume: 4 | Issue: 6 | Pages: 628-635

10.1161/circimaging.111.966341 | PMID 21946702 Get It

Background— Real-time myocardial contrast echocardiography permits the detection of myocardial perfusion abnormalities during stress echocardiography, which may improve the accuracy of the test in detecting coronary artery stenoses. We hypothesized that this technique could be used after a bolus injection of the selective A2A receptor agonist regadenoson to rapidly and safely detect coronary artery stenoses. Methods and Results— In 100 patients referred for quantitative coronary angiography, real-time myocardial contrast echocardiography was performed during a continuous intravenous infusion of 3% Definity at baseline and at 2-minute intervals for up to 6 minutes after a regadenoson bolus injection (400 μg). Myocardial perfusion was assessed by examination of myocardial contrast replenishment after brief high mechanical index impulses. A perfusion defect was defined as a delay (>2 seconds) in myocardial contrast replenishment in 2 contiguous segments. Wall motion was also analyzed. The overall sensitivity/specificity/accuracy for myocardial perfusion analysis in detecting a >50% diameter stenosis was 80%/74%/78%, whereas for wall motion analysis it was 60%/72%/66% ( P <0.001 for differences in sensitivity). Sensitivity for myocardial perfusion analysis was highest on images obtained during the first 2 minutes after regadenoson bolus ( P <0.001 compared with wall motion), whereas wall motion sensitivity was highest at the 4-to-6–minute period after the bolus. No significant side effects occurred after regadenoson bolus injection. Conclusions— Regadenoson real-time myocardial contrast echocardiography appears to be a feasible, safe, and rapid noninvasive method for the detection of significant coronary artery stenoses. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT0087369.
High Yield Imaging: Interventional
Smith, Michael Brent

Mayo Clinic

American Journal of Roentgenology | September 21, 2011 | Volume: 197 | Issue: 4 | Pages: W779-W779

10.2214/ajr.11.6822 Get It